Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.14 USD
-12.79 (-1.56%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Stock Market News For Feb 7, 2019
by Zacks Equity Research
U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
by Zacks Equity Research
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.
Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View
by Zacks Equity Research
Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Roche Submits sBLA to FDA for Label Expansion of Kadcyla
by Zacks Equity Research
Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
by Zacks Equity Research
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
by Zacks Equity Research
Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
by Zacks Equity Research
Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.
Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.
Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study
by Zacks Equity Research
Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.
Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results
by Zacks Equity Research
Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
by Zacks Equity Research
Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
Bristol-Myers (BMY) Beats Q4 Earnings, Withdraws Opdivo sBLA
by Zacks Equity Research
Bristol-Myers (BMY) beats earnings estimates in the fourth quarter but misses sales expectation by a slight margin. Eliquis and Opdivo continue to record solid sales.